{"id":"varivax-2016-commercial-process","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Injection site pain"},{"rate":"10-20%","effect":"Fatigue"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Fever"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":{"chemblId":"CHEMBL5844424","moleculeType":null,"molecularWeight":"711.22"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This vaccine works by introducing a weakened form of the virus to the body, which triggers an immune response and helps to build immunity against future infections. The immune system then remembers the virus and can mount a more effective response if exposed to it again in the future.","oneSentence":"VARIVAX is a live, attenuated vaccine that stimulates an immune response against the varicella-zoster virus.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:40:12.608Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of chickenpox"}]},"trialDetails":[{"nctId":"NCT03239873","phase":"PHASE3","title":"Evaluation of Immunogenicity and Safety of VARIVAX® Passage Extension 34 (PE34) Process in Children (V210-A03)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-10-17","conditions":"Varicella","enrollment":600}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"VARIVAX® 2016 Commercial Process","genericName":"VARIVAX® 2016 Commercial Process","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Biologic","firstApprovalDate":"","aiSummary":"Here's a 2-sentence factual summary of the VARIVAX 2016 Commercial Process:\n\nThe VARIVAX 2016 Commercial Process is a vaccine used to prevent varicella, a condition studied in clinical trials. According to ClinicalTrials.gov, this process is part of the VARIVAX vaccine, which has been evaluated for immunogenicity and safety in clinical trials, including NCT03239873.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}